<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842269</url>
  </required_header>
  <id_info>
    <org_study_id>223KTP12003</org_study_id>
    <nct_id>NCT01842269</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients</brief_title>
  <acronym>My-Rept_KT_P4</acronym>
  <official_title>Open Label, Randomized, Multi-center, Phase 4 Trial to Evaluate the Efficacy and Safety of My-Rept® Tablet(Mycophenolate Mofetil 500mg/Tab.) Versus My-Rept® Capsule(Mycophenolate Mofetil 250mg/Cap.) in Combination With Tacrolimus for 26 Weeks in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of My-Rept® Tablet(Mycophenolate Mofetil 500mg/Tab.) versus My-Rept®
      Capsule(Mycophenolate Mofetil 250mg/Cap.) in Combination with Tacrolimus in Kidney Transplant
      Patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of efficacy failure</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>efficacy failure=acute rejection by kidney biopsy,graft loss, death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute rejection by kidney biopsy</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival with no graft loss</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR(using by MDRD method)</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>Rate of adverse events
Evaluated safety parameters included: Physical examination, laboratory test, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>My-Rept® Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>My-Rept® Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil 500mg</intervention_name>
    <arm_group_label>My-Rept® Tablet</arm_group_label>
    <other_name>My-Rept® Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil 250mg</intervention_name>
    <arm_group_label>My-Rept® Capsule</arm_group_label>
    <other_name>My-Rept® Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20 years or older.

          2. Patient who receive primary or secondary kidney transplantation from living or
             brain-dead donor .

          3. Patient who receive age 20 years or older donor.

          4. Willing and able to provide written informed consent.

        Exclusion Criteria:

          1. Cold Ischemia Time &gt; 30 hours.

          2. Patient who receive HLA-identical donor.

          3. Patient with dual kidney transplantation recipient or have history of other organ
             transplantation in past or current.

          4. Patient who receive extra-renal solid organ or bone marrow stem cell transplantation.

          5. Patient who receive kidney transplantation from non-heart beating cadaveric
             donor(organ donor after cardiac death

          6. Patient who receive kidney transplantation from ABO blood type mismatching donor or
             lymphocyte cross matching (LCM) positive donor.

          7. Patient with cancer within 5 years, except cured skin cancer patient(Squamous cell or
             basal cell carcinoma)

          8. Positive in serology test(HIV, HBsAg, HCV) in recipients and/or donor.

          9. Patient with Severe gastrointestinal disease in screening period by investigator's
             decision.

         10. Patient with systemic severe infection requiring treatment (able to transplantation
             after completely disappear or is controlled infection)

         11. Liver cirrhosis, clinically significant portal hypertension or other moderate to
             severe liver disease.

         12. Defined by the following laboratory parameters before screening period

               1. One of liver function test(AST, ALT, ALP, Total Bilirubin)results increased more
                  than 3 times upper limit of normal range

               2. WBC &lt;2,500/mm3, Platelet &lt;75,000/mm3

         13. Acute (within 4 weeks) or chronic(need to treatments) allergic/hypersensitivity
             reaction in the history of Investigational drugs (ex, mycophenolate acid or
             tacrolimus, etc.) or additives.

         14. Administration of other Investigational drugs and/or immunosuppressants within 28days
             before screening period (except allowed immunosuppressants in protocol)

         15. Women in pregnant or breast-feeding or don't using adequate contraception.

         16. Patient has conversation impairment because alcohol or drugs addiction history within
             6months or mental illness, etc.

         17. In investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Seun Kim, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maryknoll Medical Center</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chunbuk National University Hospital</name>
      <address>
        <city>Chonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University School of Medical &amp; Hospital</name>
      <address>
        <city>Iksan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang CHA Medical Center</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kandong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>MMF</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

